Comparative efficacy study of experimental chronic heart failure

Comparative efficacy study of experimental chronic heart failure

Introduction. Combination therapy of chronic heart failure (CHF) is an urgent and important treatment strategy, as it allows to achieve an improvement in the prognosis, optimal control of the symptoms of the disease and an increase in the quality of life of patients.Aim. Comparison of the effectiven...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. Yu. Ivkin, A. B. Zelentsova, M. V. Krasnova, A. A. Karpov, V. V. Pazheltsev, S. M. Napalkova, I. I. Terninko, I. A. Titovich, S. V. Okovitiy
Format:	Article
Language:	Russian
Published:	LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2025-03-01
Series:	Разработка и регистрация лекарственных средств
Subjects:	empagliflozin etmaben rat hplc
Online Access:	https://www.pharmjournal.ru/jour/article/view/2009
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development and Validation of an HPLC-MS/MS Method for the Quantitative Determination of Etmaben in Human Blood Plasma
by: P. K. Karnakova, et al.
Published: (2024-03-01)

Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
by: D. P. Golubovskaya, et al.
Published: (2023-05-01)

2023 Updated European Society of Cardiology guidelines on heart failure
by: A. G. Rakisheva, et al.
Published: (2024-06-01)

Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range
by: S. V. Nedogoda, et al.
Published: (2023-07-01)

The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
by: Alexey A. Nekrasov, et al.
Published: (2019-10-01)

Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts
by: A. S. Galyavich, et al.
Published: (2022-02-01)

Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial
by: Yu. M. Lopatin, et al.
Published: (2022-04-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
by: E. V. Kovalenko, et al.
Published: (2021-02-01)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
by: Marina V. Shestakova
Published: (2019-12-01)

Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2023-04-01)

End-to-end Standardization of Original Medicines when Determining Related Impurities
by: Yu. E. Generalova, et al.
Published: (2023-12-01)

Heart Failure and Wide QRS: Clinical and Pharmacological Perspectives
by: Alfredo Mauriello, et al.
Published: (2025-06-01)

Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats
by: Mahdieh Anoush, et al.
Published: (2025-06-01)

Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis
by: Qingkai Yan, et al.
Published: (2024-11-01)

Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts
by: A. Yu. Lebedeva, et al.
Published: (2021-03-01)

Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway
by: Monika Kloza, et al.
Published: (2025-03-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Electrophysiological remodeling of the right ventricle in experimental heart failure of different etiologies
by: A. S. Tsvetkova, et al.
Published: (2019-08-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice
by: Xiehong Liu, et al.
Published: (2025-04-01)

Quantification of a potential anticonvulsant drug GIZh-298 in rat plasma by liquid chromatography-mass spectrometry
by: P. O. Bochkov, et al.
Published: (2022-12-01)

Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction
by: D. Yu. Ivkin, et al.
Published: (2023-12-01)

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
by: Ashot A. Avagimyan, et al.
Published: (2025-02-01)

Enhanced therapy for coronary artery disease and diabetes mellitus: impact on biomarkers and clinical outcomes
by: S.V. Fedorov, et al.
Published: (2024-05-01)

Preliminary Study: Expulsive Effect of Empagliflozin on Small Lower Ureteric Stones in Type II Diabetic Patients
by: Alsayed S. Abdelaziz, et al.
Published: (2024-01-01)

THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
by: M. V. Shestakova, et al.
Published: (2016-05-01)

Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial
by: G. P. Arutyunov, et al.
Published: (2020-12-01)

Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study
by: N. S. Dubovik, et al.
Published: (2022-05-01)

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2023-12-01)

New possibilities of nephroprotection in patients with chronic heart failure in combination with chronic kidney disease and diabetes mellitus 2 or without it
by: E. V. Kovalenko, et al.
Published: (2022-10-01)

Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study
by: A. G. Ovchinnikov, et al.
Published: (2021-02-01)

LC-MS/MS assisted pharmacokinetic and tissue distribution study of ropivacaine and 3-OH-ropivacaine on rats after plane block anesthesia
by: Mihaela Butiulca, et al.
Published: (2025-01-01)

A Human Engineered Heart Tissue‐Derived Lipotoxic Diabetic Cardiomyopathy Model Revealed Early Benefits of Empagliflozin
by: Lin Cai, et al.
Published: (2025-08-01)

Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01)

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
by: Ramazan Çakmak, et al.
Published: (2025-01-01)

The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide
by: I. I. Yaichkov, et al.
Published: (2025-06-01)

The influence of metformin and empagliflozin administration on gut microbiota in individuals with type 2 diabetes mellitus and hypothyroidism
by: K.A. Moskva, et al.
Published: (2024-06-01)

Experimental determination of the accumulation of cadmium salts in the heart of the embryo of rat and their effect on rat cardiogenesis
by: E. A. Nefedova, et al.
Published: (2020-10-01)

Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations
by: N. R. Khasanov
Published: (2022-02-01)

Empagliflozin Repurposing for Lafora Disease: A Pilot Clinical Trial and Preclinical Investigation of Novel Therapeutic Targets
by: Giuseppe d’Orsi, et al.
Published: (2025-05-01)